Pharma BD Deal Intelligence
AstraZeneca and Daiichi Sankyo entered a global collaboration to jointly develop and commercialize trastuzumab deruxtecan (Enhertu) in a deal worth up to…
AstraZeneca turns again to Daiichi Sankyo for a major cancer drug deal. AstraZeneca paid $1.35 billion upfront to license Enhertu in 2019 in a deal that could…
AstraZeneca and Daiichi Sankyo entered into a global collaboration to jointly develop and commercialise Enhertu in March 2019, with AstraZeneca paying…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
AstraZeneca entered a global licensing and co-development collaboration with Daiichi Sankyo for Enhertu (trastuzumab deruxtecan), a HER2-directed antibody-drug conjugate. AstraZeneca paid $1.35 billion upfront with up to $5.55 billion in regulatory and sales milestones, for a total potential deal value of $6.9 billion. Daiichi Sankyo retained exclusive rights in Japan and manufacturing responsibility.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / Daiichi Sankyo Company, Limited (this deal) | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
| AstraZeneca PLC / CinCor Pharma Inc. | 2023 | $1.8B | 78 |
← Browse all deals · How we score deals
More: 2019 deals · AstraZeneca PLC deals · Oncology deals